TAO Synergies Inc.
TAO Synergies Inc. (Nasdaq Capital Market: TAOX) operates as a diversified company pursuing two distinct strategic initiatives: a cryptocurrency treasury strategy focused on artificial intelligence digital assets and legacy biopharmaceutical development programs. The company's website is located at… From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What TAO Synergies Inc. does
In the company’s own words
TAO Synergies Inc. (Nasdaq Capital Market: TAOX) operates as a diversified company pursuing two distinct strategic initiatives: a cryptocurrency treasury strategy focused on artificial intelligence digital assets and legacy biopharmaceutical development programs. The company's website is located at www.taosynergies.com.
The company was formerly known as Synaptogenix, Inc., which itself was spun off from Neurotrope, Inc. in December 2020. Synaptogenix had operated exclusively as a biopharmaceutical company developing drug candidates for neurodegenerative diseases, particularly Alzheimer's disease. In June 2025, following exploration of strategic opportunities by an independent special committee, the company pivoted toward a cryptocurrency treasury strategy and rebranded as TAO Synergies Inc.
The primary focus of TAO Synergies' current strategy involves accumulating and staking TAO, the native cryptocurrency of Bittensor, a decentralized blockchain network for machine learning and artificial intelligence. The company allocates excess cash—defined as amounts exceeding approximately 1.5 to 2.0 years of projected operating needs—toward purchasing TAO tokens. As of September 2025, approximately 88 percent of the company's treasury holdings were invested in TAO. The company stakes TAO through custodial arrangements with BitGo Bank and Trust, N.A., and engages validators including tao5 and Yuma to facilitate staking activities and earn protocol emissions. The company also launched The TAO Daily in September 2025, a media and news platform dedicated to Bittensor and the TAO ecosystem.
The company's legacy biopharmaceutical operations focus on developing Bryostatin-1, a drug candidate for treating Alzheimer's disease and other neurodegenerative conditions including Fragile X syndrome and multiple sclerosis. The company holds an exclusive non-transferable license to patents and technologies from Cognitive Research Enterprises, Inc. and its affiliate. Previous Phase 2 clinical trials of Bryostatin-1 in moderate to severe Alzheimer's disease patients did not achieve statistical significance on primary endpoints, though secondary analyses showed signals in specific patient subpopulations. The company maintains collaborations with research institutions including Nemours and Cleveland Clinic, though the Cleveland Clinic agreement was terminated in December 2024 to reduce cash burn.
Company details
- Sector
- Financials
- Industry (SIC)
- Finance Services
- Headquarters
- NEW YORK, NY
- Fiscal year end
- December
- CIK
- 1571934
- SIC
- 6199
Financial performance, year by year
Fiscal 2020–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns TAO Synergies Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · TAO Synergies Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do TAO Synergies Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of TAO Synergies Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in TAO Synergies Inc.'s last four quarterly filings that the numbers alone won't show?”